Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
Phase 2
Completed
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02231918
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual® Respimat® solution for inhalation
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2006
- Registration Number
- NCT02231359
Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT02231177
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual® Respimat® - inhaler
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 236
- Registration Number
- NCT02231320
Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
Phase 4
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: BI-Sifrol®
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02231905
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Phase 3
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02231164
- Locations
- 🇺🇸
1199.128.10032 Boehringer Ingelheim Investigational Site, Chandler, Arizona, United States
🇺🇸1199.128.10041 Boehringer Ingelheim Investigational Site, Fayetteville, Arkansas, United States
🇺🇸1199.128.10010 Boehringer Ingelheim Investigational Site, Highland, California, United States
Observational Study to Assess a 6-months Treatment With Gladem
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 546
- Registration Number
- NCT02231268
Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02231931
- Locations
- 🇩🇪
352.2082.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 713
- Registration Number
- NCT02231424
The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1464
- Registration Number
- NCT02231294
© Copyright 2025. All Rights Reserved by MedPath